EGI
AXSM icon

EAM Global Investors’s Axsome Therapeutics AXSM Stock Holding History

EAM Global Investors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,922
Closed -$4.89M – 87
2025
Q1 		$4.89M Buy
+41,922
New +$4.78M 1.33% 24
2023
Q1 		– Sell
-21,288
Closed -$1.64M – 96
2022
Q4 		$1.64M Sell
21,288
-16,930
-44% -$1.01M 0.42% 121
2022
Q3 		$1.71M Hold
38,218
– – 0.45% 105
2022
Q2 		$1.46M Buy
+38,218
New +$1.21M 0.36% 140
2020
Q3 		– Sell
-18,569
Closed -$1.53M – 138
2020
Q2 		$1.53M Sell
18,569
-32,080
-63% -$2.47M 0.69% 72
2020
Q1 		$2.98M Buy
50,649
+10,443
+26% +$851K 1.74% 6
2019
Q4 		$4.16M Sell
40,206
-18,416
-31% -$744K 1.66% 6
2019
Q3 		$1.19M Sell
58,622
-778
-1% -$20K 0.58% 91
2019
Q2 		$1.53M Sell
59,400
-25,686
-30% -$515K 0.65% 73
2019
Q1 		$1.21M Buy
+85,086
New +$790K 0.54% 101

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EAM Global Investors's AXSM Position: Q2 2025 in Review

EAM Global Investors sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 41,922 shares — an estimated $4.89M sold.

EAM Global Investors first reported a position in AXSM in Q1 2019 and held it in 10 quarters. The position peaked at $4.89M in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • EAM Global Investors reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EAM Global Investors sold 41,922 Axsome Therapeutics shares in Q2 2025, an estimated $4.89M.
  • EAM Global Investors first reported a position in Axsome Therapeutics in Q1 2019 and held it in 10 quarters.
  • EAM Global Investors's Axsome Therapeutics position peaked at $4.89M in Q1 2025.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on EAM Global Investors's 13F filing for Q2 2025, filed 12 Aug 2025.